Document Detail


First trimester screening of maternal placental protein 13 for predicting preeclampsia and small for gestational age: in-house study and systematic review.
MedLine Citation:
PMID:  22748852     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To describe normative levels of PP13 in first trimester of pregnancy and determine the accuracy of PP13 in predicting preeclampsia and small for gestational age (SGA) infants.
METHODS: We measured PP13 in archived first trimester serum samples from an unselected maternal cohort of 2989 women. Associations of PP13 levels and diagnostic accuracy in predicting adverse pregnancy outcomes were assessed using multivariate logistic regression models. Due to inadequate number of cases we then conducted a systematic review and subsequent meta-analysis of predictive accuracy. Structured searches including all languages were completed in electronic databases and supplemented by cross-checking reference lists of relevant publications. Characteristics, data extraction and quality assessment of studies was conducted by independent assessors.
RESULTS: Overall, 2678 women were included in the in-house study with 71 (2.7%) preeclampsia cases, 5 (0.2%) early-onset preeclampsia (≤34 weeks) cases; and 191 (7.1%) and 41 (1.5%) infants SGA<10th and <3rd centile. Median (IQR) normative level of PP13 in unaffected pregnancies was 53.5 (37.7-71.8) pg/ml. The area under the receiver operating characteristic curve (AUC) for multivariate models was 0.72 (95%CI 0.66-0.78) for preeclampsia; 0.82 (95%CI 0.63-0.99) for early-onset preeclampsia; 0.73 (95%CI 0.69-0.77) for SGA<10th centile; and 0.83 (95%CI 0.78-0.88) for SGA<3rd centile. Eight studies were included in the systematic review, normative levels of PP13 were assessed in four studies but these were variable; and meta-analysis was performed on seven studies. Sensitivity rates of PP13 based on 5% fixed false positive rates were 24%, 45% and 26% for preeclampsia, for early-onset preeclampsia and SGA, respectively. There was no evidence of between-study heterogeneity.
CONCLUSIONS: First trimester PP13, in combination with maternal characteristics and other serum biomarkers was inadequate for screening purposes and predicting women at risk.
Authors:
F J Schneuer; N Nassar; A Z Khambalia; V Tasevski; C Guilbert; A W Ashton; J M Morris; C L Roberts
Publication Detail:
Type:  Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review     Date:  2012-06-28
Journal Detail:
Title:  Placenta     Volume:  33     ISSN:  1532-3102     ISO Abbreviation:  Placenta     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-08-20     Completed Date:  2013-01-03     Revised Date:  2013-01-23    
Medline Journal Info:
Nlm Unique ID:  8006349     Medline TA:  Placenta     Country:  England    
Other Details:
Languages:  eng     Pagination:  735-40     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Elsevier Ltd. All rights reserved.
Affiliation:
Clinical and Population Perinatal Health Research, Kolling Institute of Medical Research, University of Sydney, Sydney, NSW, Australia. francisco.schneuer@sydney.edu.au
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Biological Markers / blood
Female
Galectins / blood*
Gestational Age
Humans
Infant, Newborn
Infant, Small for Gestational Age / blood*
Mass Screening
Pre-Eclampsia / blood*
Pregnancy
Pregnancy Proteins / blood*
Pregnancy Trimester, First
Sensitivity and Specificity
Chemical
Reg. No./Substance:
0/Biological Markers; 0/Galectins; 0/LGALS13 protein, human; 0/Pregnancy Proteins
Comments/Corrections
Comment In:
Placenta. 2012 Nov;33(11):955; author reply 956   [PMID:  23036151 ]
Erratum In:
Placenta. 2012 Nov;33(11):957

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Glycodelin-A modulates syncytialization of human BeWo choriocarcinoma cell line.
Next Document:  [Fospropofol: A new prodrug of propofol].